Iterum Therapeutics Plc Stock News

Iterum will Continue to be Listed and Traded on the Nasdaq Stock Market Iterum will Continue to be Listed and Traded on the Nasdaq Stock Market

Iterum Therapeutics plc (NASDAQ:ITRM ) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Louise Barrett - Senior Vice President, Legal Affairs Corey Fishman - Chief Executive Officer Judith Matthews - Chief Financial Officer Conference Call Participants Thomas Yip - HC Wainwright Jason Mccarthy - Maxim Group Operator Hello, everyone, and thank you for holding, a...

- - ORLYNVAH TM Approved by FDA on October 25, 2024— --Company to Host Conference Call Today at 8:30 a.m. EDT-- DUBLIN and CHICAGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), (Iterum), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today r...

Iterum Therapeutics plc (NASDAQ:ITRM ) U.S. FDA Approval of ORLYNVAH October 28, 2024 8:30 AM ET Company Participants Louise Barrett - SVP, Legal Affairs & Secretary Corey Fishman - President, Director & CEO Steven Aronin - SVP & Head, Clinical Development Conference Call Participants Operator Hello, everyone, and welcome to Iterum Therapeutics call to discuss the recent approval of ORLYNVAH th...

Monday, October 28, 2024, at 8:30 a.m. EDT DUBLIN and CHICAGO , Oct. 28, 2024 /PRNewswire/ -- WHO: Iterum Therapeutics plc (Nasdaq: ITRM) is focused on deliveringdifferentiated anti-infectives aimed at combatting the global crisis of multi-drugresistant pathogens to significantly improve the lives of people affected byserious and life-threatening diseases around the world.

ORLYNVAH ™ is the first oral penem approved for use in the U.S. and the second FDA-approved treatment for uUTIs in the past two decades

The U.S. Food and Drug Administration has approved Iterum Therapeutics' oral antibiotic to treat a type of urinary tract infection (UTI) in adult women, the health regulator said on Friday.

DUBLIN and CHICAGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that three posters will be presented at the Infectious Disease Societ...